SPRO Spero Therapeutics, Inc.
$1.14▲ +6.54%
Healthcare
Other
Volume 507.3K
Avg Volume (10D) 374.4K
Key Metrics & Fundamentals
Market Cap
$66.39M
P/E Ratio
8.1
Div Yield
0.00%
52W Range
1.04 - 3.08
% vs 50 MA
-3.45%
% vs 200 MA
-43.10%
RSI-14
47.7
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.46
Free Cash Flow
-$5.36M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$9.93M
COGS
–
Operating Exp
$9.93M
Operating Income
-$9.93M
EBIT
-$9.93M
Pretax Income
-$9.55M
Net Income
-$9.55M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
GlobeNewswire · Oct 26, 2026 8:00 AM ET
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
MarketBeat · Oct 21, 2026 2:02 AM ET
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
GlobeNewswire · Oct 15, 2026 4:05 PM ET
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
GlobeNewswire · Oct 12, 2026 1:00 PM ET
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:05 PM ET
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 4:05 PM ET
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 2, 2026 4:01 PM ET
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 5:28 PM ET
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 8:30 AM ET
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
GuruFocus.com · Aug 13, 2026 1:01 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See SPRO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.